We collected 28 HER2-positive breast cancer samples from 20 patients who underwent neoadjuvant therapy, including 12 pre-treatment samples from patients who achieved pCR, 8 pre-treatment samples and 8 matched post-treatment samples from 8 patients who did not (non-pCR). The gene discussed is ERBB2; the disease is breast carcinoma.